ENMD-2076, an Aurora A and angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases; used to treat tumor regression in various xenograft models, such as breast, colon, and leukemia; an activity towards ex vivo-treated human leukemia patient cells; and in Phase 1 clinical studies to treat solid tumors and multiple myeloma.
George, Thank you. What a concise education for the lay people.
Guess it helps us understand that ENMD is a the right track, but still seems they need backing to succeed. Amgen would be a good fit but ENMD doesn't have any staff to promote their work to them. Gonna take a clinical results release to get the word out?????
PS. Tried to give you a five star rating and Yahoo made it a 1 star...sorry. . Accurate